Tempus, a Chicago, IL-based technology company that is building a large library of molecular and clinical data and an operating system to make that data accessible and useful, closed a $70M Series C funding round.
The round – which brings the total funding to $130M – was co-led by New Enterprise Associates (NEA) and Revolution Growth.
Led by Eric Lefkofsky, Founder and CEO, Tempus has spent the last two years building a series of data pipelines to collect, cleanse, and analyze data at scale, utilizing a cloud-based platform, cluster computing, next generation sequencing, natural language processing and AI-assisted image recognition.
These data pipelines power proprietary software applications designed to drive clinical decision support and cutting edge academic research.
The company has collaborations in place with hospitals such as Cleveland Clinic, Duke University School of Medicine, Mayo Clinic, Northwestern’s Lurie Cancer Center, Penn’s Abramson Cancer Center, University of Chicago Medicine, University of Michigan and community hospitals across the country.